Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation

Gynecologic Oncology

Volumn 126, Issue 3, 2012, Pages 466-473

  Nout, Remi A ^a   Bosse, Tjalling ^a   Creutzberg, Carien L ^a   Jürgenliemk Schulz, Ina M ^b   Jobsen, Jan J ^c   Lutgens, Ludy C H W ^d   Van Der Steen Banasik, Elzbieta M ^e   Van Eijk, Ronald ^a   Ter Haar, Natalja T ^a   Smit, Vincent T H B M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d MAASTtricht Radiation Oncology Clinic   (Netherlands)

^e Radiotherapy Institute Arnhem   (Netherlands)

Author keywords

Endometrial cancer; Microsatellite instability; Oncogenic pathway alterations; P53 mutation; PI3K AKT pathway; Wnt signaling pathway

Indexed keywords

BETA CATENIN; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; STATHMIN; WNT PROTEIN;

ADULT; AGED; BRACHYTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONFERENCE PAPER; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; DNA ISOLATION; EMBEDDING; ENDOMETRIUM CANCER; ENZYME ACTIVATION; EXON; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; AGED, 80 AND OVER; BETA CATENIN; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; EXONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; METHYLATION; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RISK ASSESSMENT; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; WNT SIGNALING PATHWAY;

EID: 84864413479     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.05.012     Document Type: Conference Paper

References (35)

1. F. Bray, A.H. Loos, M. Oostindier, and E. Weiderpass Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre- and postmenopausal women in Europe Int J Cancer 117 2005 123 131 (Pubitemid 41262766)
2. F. Amant, P. Moerman, P. Neven, D. Timmerman, L.E. Van, and I. Vergote Endometrial cancer Lancet 366 2005 491 505 (Pubitemid 41111699)
3. P.G. Rose Endometrial carcinoma N Engl J Med 335 1996 640 649 (Pubitemid 26277956)
4. C.L. Creutzberg, and R.A. Nout The role of radiotherapy in endometrial cancer: current evidence and trends Curr Oncol Rep 13 2011 472 478
5. C.L. Creutzberg, W.L. van Putten, P.C. Koper, M.L. Lybeert, J.J. Jobsen, and C.C. Warlam-Rodenhuis Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma Lancet 355 2000 1404 1411 (Pubitemid 30215963)
6. H.M. Keys, J.A. Roberts, V.L. Brunetto, R.J. Zaino, N.M. Spirtos, and J.D. Bloss A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study Gynecol Oncol 92 2004 744 751 (Pubitemid 38251372)
7. R.A. Nout, V.T. Smit, H. Putter, I.M. Jurgenliemk-Schulz, J.J. Jobsen, and L.C. Lutgens Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial Lancet 375 2010 816 823
8. K.J. Dedes, D. Wetterskog, A. Ashworth, S.B. Kaye, and J.S. Reis-Filho Emerging therapeutic targets in endometrial cancer Nat Rev Clin Oncol 8 2011 261 271
9. I.B. Engelsen, L.A. Akslen, and H.B. Salvesen Biologic markers in endometrial cancer treatment APMIS 117 2009 693 707
10. N. Samarnthai, K. Hall, and I.T. Yeh Molecular profiling of endometrial malignancies Obstet Gynecol Int 2010 2010 162363
11. K. Oda, J. Okada, L. Timmerman, P. Rodriguez-Viciana, D. Stokoe, and K. Shoji PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation Cancer Res 68 2008 8127 8136
12. H.B. Salvesen, S.L. Carter, M. Mannelqvist, A. Dutt, G. Getz, and I.M. Stefansson Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation Proc Natl Acad Sci U S A 106 2009 4834 4839
13. L. Catasus, A. Gallardo, M. Cuatrecasas, and J. Prat Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis Mod Pathol 22 2009 522 529
14. R. van Eijk, J. Licht, M. Schrumpf, Y.M. Talebian, D. Ruano, and G.I. Forte Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR PLoS One 6 2011 e17791
15. C.R. Boland, S.N. Thibodeau, S.R. Hamilton, D. Sidransky, J.R. Eshleman, and R.W. Burt A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer Cancer Res 58 1998 5248 5257 (Pubitemid 28521189)
16. E.H. van Roon, M. van Puijenbroek, A. Middeldorp, R. van Eijk, E.J. de Meijer, and D. Erasmus Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? BMC Cancer 10 2010 180
17. C.E. da Costa, K. Szuhai, R. van Eijk, M. Hoogeboom, R. Sciot, and F. Mertens No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies Genes Chromosomes Cancer 48 2009 239 249
18. L. Lomo, M.R. Nucci, K.R. Lee, M.C. Lin, M.S. Hirsch, and C.P. Crum Histologic and immunohistochemical decision-making in endometrial adenocarcinoma Mod Pathol 21 2008 937 942
19. J. Trovik, E. Wik, I. Stefansson, S.L. Carter, R. Beroukhim, and A.M. Oyan Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer Histopathology 57 2010 641 646
20. D. Black, R.A. Soslow, D.A. Levine, C. Tornos, S.C. Chen, and A.J. Hummer Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma J Clin Oncol 24 2006 1745 1753 (Pubitemid 46622146)
21. H.J. Mackay, S. Gallinger, M.S. Tsao, C.M. McLachlin, D. Tu, and K. Keiser Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG) Eur J Cancer 46 2010 1365 1373
22. A. Percesepe, F. Borghi, M. Menigatti, L. Losi, M. Foroni, and G.C. Di Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study J Clin Oncol 19 2001 3944 3950 (Pubitemid 32912021)
23. I. Zighelboim, P.J. Goodfellow, F. Gao, R.K. Gibb, M.A. Powell, and J.S. Rader Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type J Clin Oncol 25 2007 2042 2048 (Pubitemid 46972789)
24. K. Wang, J. Kan, S.T. Yuen, S.T. Shi, K.M. Chu, and S. Law Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer Nat Genet 43 2011 1219 1223
25. B. Guan, T.L. Wang, and I. Shih ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers Cancer Res 71 2011 6718 6727
26. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657 (Pubitemid 34579158)
27. P. Rodriguez-Viciana, P.H. Warne, R. Dhand, B. Vanhaesebroeck, I. Gout, and M.J. Fry Phosphatidylinositol-3-OH kinase as a direct target of Ras Nature 370 1994 527 532 (Pubitemid 24264918)
28. Y. Samuels, and K. Ericson Oncogenic PI3K and its role in cancer Curr Opin Oncol 18 2006 77 82 (Pubitemid 43740454)
29. T.L. Yuan, and L.C. Cantley PI3K pathway alterations in cancer: variations on a theme Oncogene 27 2008 5497 5510
30. T.H. Kim, J. Wang, K.Y. Lee, H.L. Franco, R.R. Broaddus, and J.P. Lydon The synergistic effect of conditional Pten loss and oncogenic K-ras mutation on endometrial cancer development occurs via decreased progesterone receptor action J Oncol 2010 2010 139087
31. L.H. Saal, P. Johansson, K. Holm, S.K. Gruvberger-Saal, Q.B. She, and M. Maurer Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity Proc Natl Acad Sci U S A 104 2007 7564 7569 (Pubitemid 47185946)
32. J. Ahn, M. Murphy, S. Kratowicz, A. Wang, A.J. Levine, and D.L. George Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction Oncogene 18 1999 5954 5958 (Pubitemid 29520452)
33. J.I. Johnsen, O.N. Aurelio, Z. Kwaja, G.E. Jorgensen, N.S. Pellegata, and R. Plattner p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest Int J Cancer 88 2000 685 691
34. M. Murphy, J. Ahn, K.K. Walker, W.H. Hoffman, R.M. Evans, and A.J. Levine Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a Genes Dev 13 1999 2490 2501 (Pubitemid 29489641)
35. C.H. Yeang, F. McCormick, and A. Levine Combinatorial patterns of somatic gene mutations in cancer FASEB J 22 2008 2605 2622